Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.
The effects of small oral doses (1-2 microgram/day) of 1alpha-hydroxycholecalciferol, given for 1 to 2 years, have been examined in four nondialysed adolescents with chronic renal failure and bone disease. Treatment increased calcium retention and plasma calcium, and decreased plasma levels of alkal...
Main Authors: | Kanis, J, Henderson, R, Heynen, G, Ledingham, J, Russell, R, Smith, R, Walton, R |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado: |
1977
|
Títulos similares
-
1,25-dihydroxycholecalciferol and 1alpha-hydroxycholecalciferol in hypoparathyroidism.
por: Russell, R, et al.
Publicado: (1974) -
EVIDENCE THAT ENDOGENOUS CALCITONIN PROTECTS AGAINST RENAL BONE-DISEASE
por: Heynen, G, et al.
Publicado: (1976) -
Correlation of clinical, biochemical and skeletal responses to 1alpha-hydroxyvitamin D3 in renal bone disease.
por: Kanis, J, et al.
Publicado: (1977) -
Factors influencing the response to 1alpha-hydroxyvitamin D3 in patients with renal bone disease.
por: Kanis, J, et al.
Publicado: (1977) -
THERAPEUTIC ADVANTAGE OF 1-ALPHA-HYDROXYLATED COMPOUNDS OVER VITAMIN-D
por: Kanis, J, et al.
Publicado: (1977)